194 related articles for article (PubMed ID: 31454678)
1. Anti-Angiogenic and Anti-Scarring Dual Action of an Anti-Fibroblast Growth Factor 2 Aptamer in Animal Models of Retinal Disease.
Matsuda Y; Nonaka Y; Futakawa S; Imai H; Akita K; Nishihata T; Fujiwara M; Ali Y; Bhisitkul RB; Nakamura Y
Mol Ther Nucleic Acids; 2019 Sep; 17():819-828. PubMed ID: 31454678
[TBL] [Abstract][Full Text] [Related]
2. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.
Becerra EM; Morescalchi F; Gandolfo F; Danzi P; Nascimbeni G; Arcidiacono B; Semeraro F
Curr Drug Targets; 2011 Feb; 12(2):149-72. PubMed ID: 20887246
[TBL] [Abstract][Full Text] [Related]
3. Development of gene therapy for treatment of age-related macular degeneration.
Askou AL
Acta Ophthalmol; 2014 Jul; 92 Thesis3():1-38. PubMed ID: 24953666
[TBL] [Abstract][Full Text] [Related]
4. New Therapies of Neovascular AMD-Beyond Anti-VEGFs.
Yerramothu P
Vision (Basel); 2018 Jul; 2(3):. PubMed ID: 31735894
[TBL] [Abstract][Full Text] [Related]
5. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.
Eyetech Study Group
Retina; 2002 Apr; 22(2):143-52. PubMed ID: 11927845
[TBL] [Abstract][Full Text] [Related]
6. Anti-angiogenic biomolecules in neovascular age-related macular degeneration; therapeutics and drug delivery systems.
Kazemi MS; Shoari A; Salehibakhsh N; Aliabadi HAM; Abolhosseini M; Arab SS; Ahmadieh H; Kanavi MR; Behdani M
Int J Pharm; 2024 May; 659():124258. PubMed ID: 38782152
[TBL] [Abstract][Full Text] [Related]
7. Co-inhibition of PGF and VEGF blocks their expression in mononuclear phagocytes and limits neovascularization and leakage in the murine retina.
Balser C; Wolf A; Herb M; Langmann T
J Neuroinflammation; 2019 Feb; 16(1):26. PubMed ID: 30732627
[TBL] [Abstract][Full Text] [Related]
8. Secretogranin III as a novel target for the therapy of choroidal neovascularization.
LeBlanc ME; Wang W; Ji Y; Tian H; Liu D; Zhang X; Li W
Exp Eye Res; 2019 Apr; 181():120-126. PubMed ID: 30633921
[TBL] [Abstract][Full Text] [Related]
9. An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration.
Feng L; Hu JH; Chen J; Xie X
J Zhejiang Univ Sci B; 2018 Apr.; 19(4):327-332. PubMed ID: 29616508
[TBL] [Abstract][Full Text] [Related]
10. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results.
Eyetech Study Group
Ophthalmology; 2003 May; 110(5):979-86. PubMed ID: 12750101
[TBL] [Abstract][Full Text] [Related]
11. Topical application of a G-Quartet aptamer targeting nucleolin attenuates choroidal neovascularization in a model of age-related macular degeneration.
Leaderer D; Cashman SM; Kumar-Singh R
Exp Eye Res; 2015 Nov; 140():171-178. PubMed ID: 26368850
[TBL] [Abstract][Full Text] [Related]
12. New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD).
Patel P; Sheth V
J Clin Med; 2021 May; 10(11):. PubMed ID: 34070899
[TBL] [Abstract][Full Text] [Related]
13. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
Emerson MV; Lauer AK
BioDrugs; 2007; 21(4):245-57. PubMed ID: 17628122
[TBL] [Abstract][Full Text] [Related]
14. Axitinib inhibits retinal and choroidal neovascularization in in vitro and in vivo models.
Giddabasappa A; Lalwani K; Norberg R; Gukasyan HJ; Paterson D; Schachar RA; Rittenhouse K; Klamerus K; Mosyak L; Eswaraka J
Exp Eye Res; 2016 Apr; 145():373-379. PubMed ID: 26927930
[TBL] [Abstract][Full Text] [Related]
15. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.
Waisbourd M; Loewenstein A; Goldstein M; Leibovitch I
Drugs Aging; 2007; 24(8):643-62. PubMed ID: 17702534
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of experimental choroidal neovascularization in mice by anti-VEGFA/VEGFR2 or non-specific siRNA.
Gu L; Chen H; Tuo J; Gao X; Chen L
Exp Eye Res; 2010 Sep; 91(3):433-9. PubMed ID: 20599960
[TBL] [Abstract][Full Text] [Related]
17. Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro.
Siedlecki J; Wertheimer C; Wolf A; Liegl R; Priglinger C; Priglinger S; Eibl-Lindner K
Graefes Arch Clin Exp Ophthalmol; 2017 May; 255(5):963-972. PubMed ID: 28161830
[TBL] [Abstract][Full Text] [Related]
18. Theoretical Insights into the Retinal Dynamics of Vascular Endothelial Growth Factor in Patients Treated with Ranibizumab, Based on an Ocular Pharmacokinetic/Pharmacodynamic Model.
Hutton-Smith LA; Gaffney EA; Byrne HM; Caruso A; Maini PK; Mazer NA
Mol Pharm; 2018 Jul; 15(7):2770-2784. PubMed ID: 29734810
[TBL] [Abstract][Full Text] [Related]
19. Multiple Therapeutic Applications of RBM-007, an Anti-FGF2 Aptamer.
Nakamura Y
Cells; 2021 Jun; 10(7):. PubMed ID: 34203430
[TBL] [Abstract][Full Text] [Related]
20. Profile of conbercept in the treatment of neovascular age-related macular degeneration.
Lu X; Sun X
Drug Des Devel Ther; 2015; 9():2311-20. PubMed ID: 25960634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]